Our NAD+ pen holds 1000 mg of nicotinamide adenine dinucleotide in 3 ml, already in solution, as a pre-loaded multi-dose pen. It is the odd entry in a peptide catalogue because it is not a peptide at all: it is a coenzyme, and most of what confuses people about the category follows from that. The biochemistry is set out at what is NAD+. This band covers what the human trials actually measured, what exists on NAD+ given by injection, what is in the parcel, and where the pen sits in our catalogue.
A coenzyme, not a signalling peptide
NAD+ takes part directly in redox reactions, carrying electrons inside the cell, including in the mitochondrial steps that make ATP. It does not sit on a receptor and send a signal, which is what the peptides elsewhere in this catalogue do. So the receptor-selectivity question that explains almost every other product here does not apply; asking which receptor NAD+ acts on is a malformed question. What does apply is the question of how the molecule gets into the body, and that is where the precursors come in.
Precursors are not the same thing as the coenzyme
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are precursors: smaller molecules the body converts along the salvage pathway toward NAD+. They are inputs, not the destination, which is why “NAD+ vs NMN” is not a comparison between competing products but between a molecule and its own precursor. We set both out at NAD+ vs NMN and NAD+ vs nicotinamide riboside.
Size drives the practical split. NAD+ is a comparatively large molecule that is poorly absorbed by mouth, which is the usual explanation for why NAD+ itself is presented as an injectable or intravenous product while NR and NMN are sold as oral supplements. It is also why almost the whole human trial literature is about the precursors rather than about the coenzyme in this pen.
What the precursor trials measured
The trials are clear on one point: oral precursors raise blood NAD+, in proportion to dose. In an eight-week randomised, double-blind, placebo-controlled trial in overweight but otherwise healthy adults, 100, 300 and 1000 mg of NR a day raised whole-blood NAD+ by 22%, 51% and 142% within two weeks, the rise held for the rest of the study, and adverse events did not differ between NR and placebo (Conze D et al. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep 2019. PMID 31278280). A second randomised, double-blind, placebo-controlled study in 120 healthy adults aged 60 to 80 found that a nicotinamide riboside and pterostilbene combination raised whole-blood NAD+ by roughly 40% at the standard dose and roughly 90% at double the dose after four weeks, sustained across the eight-week trial (Dellinger RW et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech Dis 2017. PMID 29184669).
They are less settled on whether the raised level does anything downstream. A randomised, multicentre, double-blind, placebo-controlled trial of 80 healthy middle-aged adults taking 300, 600 or 900 mg of NMN by mouth for 60 days reported higher blood NAD at every dose, a larger gain in six-minute walking distance than placebo, and no significant difference in insulin resistance measured by HOMA-IR (Yi L et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience 2023. PMID 36482258). A meta-analysis of eight randomised controlled trials of NMN, 342 adults in total at 250 to 2000 mg a day for 14 days to 12 weeks, found no significant benefit on fasting glucose, fasting insulin, glycated haemoglobin, HOMA-IR or lipid profile (Chen F et al. Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Curr Diab Rep 2024. PMID 39531138).
| Trial | What was taken | What changed |
|---|
| Conze 2019 | NR 100–1000 mg a day, 8 weeks | Blood NAD+ up 22–142%, by dose |
| Dellinger 2017 | NR + pterostilbene, 8 weeks | Blood NAD+ up about 40–90% |
| Yi 2023 | NMN 300–900 mg a day, 60 days | Blood NAD up; walk distance up; HOMA-IR unchanged |
| Chen 2024 | NMN 250–2000 mg a day, 8 RCTs pooled | Glucose, insulin, HbA1c, lipids unchanged |
The honest summary is that the biomarker moves reliably and the downstream outcomes are inconsistent by endpoint. That is more useful than either “proven” or “debunked”, and it applies to oral precursors, which are not what is in this pen.
What exists on NAD+ given directly
The record on NAD+ itself is thin, and we would rather say so once than let the precursor trials stand in for it. The nearest published human study of the molecule on its own is a pilot in which participants received a six-hour intravenous infusion; it tracked plasma and urine metabolites, not clinical outcomes, and found NAD+ was cleared from plasma for at least the first two hours (Grant R et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci 2019. PMID 31572171). A single-centre randomised, placebo-controlled trial published in 2026 gave 180 patients with heart failure from ischaemic cardiomyopathy intravenous NAD+ for seven days alongside standard treatment and reported a larger improvement in left-ventricular ejection fraction than placebo (Yu X et al. Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial. Am J Cardiovasc Drugs 2026. PMID 40954388). That is a diagnosed disease treated under medical supervision by drip, and it says nothing about a healthy adult using a pen. No published randomised trial has tested NAD+ injected under the skin in healthy adults, so for the way this product is presented there is no human dose-response or outcome data at all.
What arrives, and how it travels
The parcel holds the pen, eight standard threaded pen needles, a printed guide and a verification sticker, and there is nothing to prepare: the NAD+ is already in solution, so there is no powder to reconstitute, which is the practical difference we set out at pen vs vial. It ships in insulated packaging with a cooling element and a temperature indicator, held at 2–8 °C from our Czech dispatch point to your refrigerator; how that works, and what the indicator tells you, is at cold-chain shipping. Orders placed before 12:00 on a business day dispatch the same day. Delivery is 3–5 business days across the EU, tracked door to door, with the tracking link by email and WhatsApp updates if you opt in. Dispatch is inside the EU, so there are no customs charges and no import paperwork.
Check the temperature indicator when the parcel arrives. If it shows a breach, or a pen arrives broken or does not work, we replace it free of charge once you send photos or a short video of the fault. Unopened, unused pens in their original sealed packaging can be returned within 30 days of delivery for a full refund to the original payment method; opened pens cannot. The full terms are at returns.
The certificate for your batch
Every batch goes to an independent laboratory, which tests it for identity by mass spectrometry, for purity by HPLC and for sterility. The certificate for your lot is reached by scanning the QR code on the pen, or from the certificate index, as a plain PDF with no account needed. It shows the purity percentage the laboratory measured and the concentration of the cartridge, in mg/ml and as total mg per 3 ml. We do not name the laboratory, and we do not publish a purity figure of our own; the certificate shows the lab’s figure for your batch, not a sample report.
Where it sits in the catalogue
NAD+ is filed under energy and longevity, and it is the pen that appears in most of our stacks. Two of them are the natural comparison. The Vitality Stack pairs it with GHK-Cu, the copper tripeptide, for people whose interest is ageing and skin. The Metabolic Reset pairs it with MOTS-C 32, a peptide encoded in mitochondrial DNA, for people whose interest is energy and metabolic signalling; the two molecules are laid out together at mitochondrial peptides and compared head to head at MOTS-c vs NAD+. In neither case has a published trial tested the two pens together, and each pen is the same product sold on its own page.
One regulatory fact belongs here. No injectable NAD+ product holds a marketing authorisation as a medicine in the European Union, and the oral precursors are generally sold as food supplements, a different framework again. Why that is the position for this and the other compounds we sell is explained at why these compounds are not EMA-authorised.
